Rafael Blesa - Sant Pau Memory Unit - Alzheimer Research - Barcelona

Rafael Blesa

Rafael Blesa GonzalezDr. Rafael Blesa obtained his medical degree from the Universitat Autònoma de Barcelona in 1975 and specialized in Neurology at Hospital de la Santa Creu i Sant Pau.

After completing his Ph.D. in Medicine at the Universitat de Barcelona (1989) he worked at the National Institute of Health in Bethesda, Maryland (USA) as an associate researcher in experimental therapies. He returned to Barcelona in 1993 where he directed the Alzheimer and Other Cognitive Disorders Unit at Hospital Clínic for 10 years. Since 2003, Dr Blesa has been the Director of the Neurology Department at Hospital de la Santa Creu i Sant Pau.

Dr. Rafael Blesa is the author of more than 30 book chapters and more than 170 scientific articles published in high impact national and international journals, and he has been the principal investigator of over 70 research projects and pharmacological studies in the field of Alzheimer’s disease. He is a member of prestigious medical and scientific societies that have awarded his scientific contributions in numerous occasions.

In his professional trajectory, he has combined clinical and research tasks with teaching activities as an associate professor of Neurology at Universitat de Barcelona and Universitat Autònoma de Barcelona, and he has directed and supervised numerous doctoral theses.

Currently, besides directing the Neurology Department, Dr. Rafael Blesa is the principal investigator of the advanced therapies research line within the Memory Unit.

 

Recent Publications

  1. Double-Edged Lipid Nanoparticles Combining Liposome-Bound TRAIL and Encapsulated Doxorubicin Showing an Extraordinary Synergistic Pro-Apoptotic Potential. De Miguel, D et al. Cancers (Basel) 2019
    PMID:31817469

  2. More Than One HMG-CoA Lyase: The Classical Mitochondrial Enzyme Plus the Peroxisomal and the Cytosolic Ones. Arnedo, M et al. Int J Mol Sci 2019
    PMID:31817290

  3. Strongyloides stercoralis: a rare and severe presentation in a pregnant woman. Beltrán Rosel, A et al. New Microbiol. 2019
    PMID:31814031

  4. Black oesophagus (acute oesophageal necrosis). Laredo, V et al. Gastroenterol Hepatol 2019
    PMID:31810795

  5. Prospective, study comparing the accuracy of two different stool antigen tests (Premier Platinum HpSA and novel ImmunoCard STAT! rapid test) for the diagnosis of Helicobacter pylori infection. McNicholl, AG et al. Gastroenterol Hepatol 2019
    PMID:31810793

  6. Effect of Training Load on Post-Exercise Cardiac Troponin T Elevations in Young Soccer Players. Cirer-Sastre, R et al. Int J Environ Res Public Health 2019
    PMID:31810338

  7. Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials. Benavides, M et al. ESMO Open 2019
    PMID:31803504

  8. Changes in thalamic dopamine innervation in a progressive Parkinson's disease model in monkeys. Monje, MHG et al. Mov. Disord. 2019
    PMID:31800134

  9. Atrophy of Basal Forebrain Initiates with Tau Pathology in Individuals at Risk for Alzheimer's Disease. Cantero, JL et al. Cereb. Cortex 2019
    PMID:31799623

  10. [Long-term palmoplantar hyperkeratosis]. Aldea Manrique, B et al. Semergen 2019
    PMID:31791848

  11. APP-derived peptides reflect neurodegeneration in frontotemporal dementia. Illán-Gala, I et al. Ann Clin Transl Neurol 2019
    PMID:31789459

  12. Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study. Pérez-Grijalba, V et al. Alzheimers Res Ther 2019
    PMID:31787105

  13. Clinical value of CT-P13 trough levels, an infliximab biosimilar, in the management of inflammatory bowel disease. Elosua González, A et al. Med Clin (Barc) 2019
    PMID:31785803

  14. Endoscopic management of nonvariceal upper gastrointestinal bleeding. Cañamares-Orbís, P et al. Best Pract Res Clin Gastroenterol
    PMID:31785733

  15. Anti-MDA5 (CADM-140) positive dermatomyositis: Mucocutaneous and soft tissue manifestations. García-Gil, MF et al. Med Clin (Barc) 2019
    PMID:31784114

Search PubMed